Dr. Sayantani Sinha
Sayantani Sinha completed her PhD from the School of Biomedical Sciences at Kent State University. In her PhD thesis work, she investigated the role of Transient receptor potential (TRP) ion channels in Propofol (Diprivan) - induced hypotension and pain induction, the two major side-effects of this anesthetic when administered during surgery. After completing her PhD, Dr. Sinha joined the Translational Research Group in Pediatric Orthopaedics at the Children’s Hospital of Philadelphia (CHOP), where she conducted translational and pre-clinical research investigating potential treatments for curing Fibrodysplasia Ossificans Progressivia (FOP), a rare but devastating pediatric condition characterized by the progressive ossification of muscle, tendons and ligaments, referred to clinically as heterotopic ossification (HO). As part of these studies, Dr. Sinha conducted pre-clinical studies using Palovarotene to block HO. Palovarotene is currently undergoing Phase III clinical trials to prevent HO in FOP patients. After completing her post-doctoral research, Dr. Sinha joined Dr. Stefano Rivella’s research team in the Division of Hematology at CHOP. She is currently working on two projects: 1) To investigate how inflammatory mediators and adaptive immune responses trigger anemia of inflammation, a clinical manifestation seen in patients with acute infections, autoimmune disorders and malignancies, and 2) To elucidate the role of transferrin receptor 2 (TFR2) in maintaining iron homeostasis and metabolism and how mutations in TFR2 leads to iron overload/ hereditary hemochromatosis.